HMGB1 and myeloid sarcoma: Some evidence suggests that high-mobility group protein 1 (HMGB1) contributes to MS through TLRs, and inhibition of HMGB1 can reduce inflammatory responses and improve cognitive and motor functions in MS patients [160].